echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Exact Sciences and General Health merged to create a cancer diagnosis company

    Exact Sciences and General Health merged to create a cancer diagnosis company

    • Last Update: 2021-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    today, Act Sciences, which specializes in cancer screening technology, and Genomic Health, a genetic testing company, announced that they will merge to form a new large cancer diagnostic company. This cooperation amounted to $2.8 billion.Exact Sciences' main product, Cologuard, was launched in 2014 as the FDA's first non-invasive fecal sampling kit, which was subsequently included in medicare coverage and multiple guidelines. Cologuard users can take their own stool samples from home and put them in kits for inspection by post. The company analyzed DNA and other biomarkers of colorectal cancer cells that may be carried in feces, including a hemoglobin, seven DNA mutations associated with the KRAS gene, DNA methylation status of the NDRG4 and BMP3 genes, and a β myosin-related biomarker). Cologuard is 92 percent sensitive to colorectal cancer detection and 87 percent specific. Cologuard, meanwhile, is 42% sensitive to detection of pre-colorectal cancer.Genomic Health's main product is Oncotype DX, which evaluates the likelihood of recurrence and provides positive guidance on treatment options by conducting five types of genetic testing for cancers such as breast cancer, early prostate cancer, and bowel cancer, giving a breast catheter in-place cancer (DCIS) score, a breast cancer recurrence index score, a genomic prostate cancer score, and a bowel cancer recurrence index.Genomic Health Oncotype DX Breast Cancer Recurrence Index Score for patients with ER-plus, HER2-, lymph node-negative breast cancer. By detecting the expression levels of 16 breast cancer-related genes and 5 reference genes in their tumor tissue, the risk of breast cancer recurrence and the benefit ratio of chemotherapy can be predicted, providing clinicians with individual treatment effectiveness prediction and 10-year recurrence risk prediction. If the patient's recurrence index score (RS) is less than 25, the patient only needs endocrine therapy, if the RS score is greater than 26, then chemotherapy will be one of the important treatment options. (Drug Ming Kant)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.